Scarica l'app Stockscreener
37.41
0.82%
-0.31
Dopo l'orario di chiusura:
37.41
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché EXEL Giù?
Forum
Previsione
Precedente Chiudi:
$37.72
Aprire:
$37.6
Volume 24 ore:
2.12M
Relative Volume:
0.58
Capitalizzazione di mercato:
$10.07B
Reddito:
$2.17B
Utile/perdita netta:
$521.27M
Rapporto P/E:
21.14
EPS:
1.77
Flusso di cassa netto:
$633.79M
1 W Prestazione:
+1.63%
1M Prestazione:
-16.61%
6M Prestazione:
+14.02%
1 anno Prestazione:
+38.71%
Intervallo 1D:
$37.27
$38.12
Intervallo di 1 settimana:
$36.37
$38.12
Portata 52W:
$25.12
$49.62
Exelixis Inc Stock (EXEL) Company Profile
Nome
Exelixis Inc
Settore
Industria
Telefono
(650) 837-7000
Indirizzo
1851 HARBOR BAY PARKWAY, ALAMEDA, CA
Confronta EXEL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EXEL
Exelixis Inc
|
37.41 | 10.15B | 2.17B | 521.27M | 633.79M | 1.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
374.46 | 93.98B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.94 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
435.00 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
638.90 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
289.75 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Exelixis Inc Stock (EXEL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-08 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-06-24 | Aggiornamento | Stephens | Equal-Weight → Overweight |
| 2025-02-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-01-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-01-24 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-12-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-17 | Downgrade | BofA Securities | Buy → Neutral |
| 2024-10-16 | Reiterato | RBC Capital Mkts | Outperform |
| 2024-09-19 | Iniziato | UBS | Neutral |
| 2024-04-11 | Downgrade | Barclays | Overweight → Equal Weight |
| 2023-12-19 | Iniziato | BTIG Research | Buy |
| 2023-12-15 | Iniziato | Citigroup | Buy |
| 2023-09-26 | Iniziato | H.C. Wainwright | Buy |
| 2023-08-22 | Reiterato | Oppenheimer | Outperform |
| 2023-08-08 | Iniziato | SVB Securities | Market Perform |
| 2023-07-11 | Ripresa | Morgan Stanley | Equal-Weight |
| 2023-05-10 | Ripresa | Piper Sandler | Overweight |
| 2023-03-09 | Iniziato | Wells Fargo | Overweight |
| 2023-01-26 | Iniziato | Credit Suisse | Outperform |
| 2022-10-18 | Iniziato | JMP Securities | Mkt Outperform |
| 2022-06-24 | Iniziato | BMO Capital Markets | Outperform |
| 2021-11-19 | Iniziato | Piper Sandler | Overweight |
| 2021-11-03 | Ripresa | Jefferies | Buy |
| 2021-10-07 | Iniziato | Jefferies | Buy |
| 2021-08-06 | Reiterato | H.C. Wainwright | Buy |
| 2021-06-15 | Iniziato | H.C. Wainwright | Buy |
| 2021-05-18 | Ripresa | Goldman | Sell |
| 2021-03-31 | Iniziato | Credit Suisse | Outperform |
| 2021-03-12 | Iniziato | Wolfe Research | Outperform |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-01-13 | Iniziato | SunTrust | Buy |
| 2019-11-13 | Iniziato | BofA/Merrill | Buy |
| 2019-03-18 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2018-09-17 | Iniziato | Goldman | Neutral |
| 2018-09-10 | Iniziato | Morgan Stanley | Underweight |
| 2018-05-11 | Reiterato | Needham | Buy |
| 2017-10-17 | Reiterato | Needham | Buy |
| 2017-10-17 | Reiterato | RBC Capital Mkts | Outperform |
| 2017-10-16 | Reiterato | SunTrust | Buy |
| 2017-09-22 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| 2017-09-15 | Iniziato | RBC Capital Mkts | Outperform |
| 2017-09-12 | Reiterato | Needham | Buy |
| 2017-07-14 | Iniziato | SunTrust | Buy |
| 2017-03-31 | Iniziato | Needham | Buy |
| 2017-03-16 | Iniziato | Oppenheimer | Perform |
| 2017-02-28 | Downgrade | Stifel | Buy → Hold |
| 2016-11-03 | Iniziato | Deutsche Bank | Buy |
| 2016-10-10 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2016-09-15 | Reiterato | Stifel | Buy |
Mostra tutto
Exelixis Inc Borsa (EXEL) Ultime notizie
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc.EXEL - PR Newswire
LPL Financial LLC Increases Position in Exelixis, Inc. (NASDAQ:EXEL) - Defense World
ATTENTION EXEL Shareholders: Lost Money on Exelixis, Inc.? Contact Levi & Korsinsky About Investigation - ACCESS Newswire
Ongoing Securities Investigation into Exelixis, Inc. (EXEL)Contact Levi & Korsinsky - ACCESS Newswire
Exelixis’ CABOMETYX Receives EU Approval for Neuroendocrine Tumor Treatment - Insider Monkey
Is Exelixis Inc. stock bottoming outPre-Market Stock Movement Summary and Review - Newser
Exelixis reports Q2 net product revenues 2% below consensus estimate. - AInvest
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Exelixis, Inc. - EXEL - GlobeNewswire Inc.
Identifying reversal signals in Exelixis Inc.Trend Confirmation Scanner with Entry Focus - Newser
Relative strength of Exelixis Inc. in sector analysisProfit Target Planning with Exit Confidence - Newser
Can Exelixis Inc. be recession proofTriple Digit Stock Opportunities - sisaissue.com
Live market analysis of Exelixis Inc.Free Daily Growth Stock Pick Reports - Newser
Lost Money on Exelixis, Inc. (EXEL)? Possible FraudContact Levi & Korsinsky Today - ACCESS Newswire
Levi & Korsinsky Investigates Exelixis, Inc. (EXEL) Over Possible Securities Fraud - ACCESS Newswire
Exelixis, Inc. (NASDAQ:EXEL) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap? - 富途牛牛
Exelixis, Inc. (NASDAQ:EXEL) Shares Sold by Mutual of America Capital Management LLC - Defense World
What Fibonacci levels say about Exelixis Inc. reboundTechnical Long-Term Outlook and Recap Guide - Newser
Momentum Screeners Rank Exelixis Inc. in Top 5 TodaySafe Entry Stock Watch Suggestions for Cautious Traders - beatles.ru
Will Exelixis Inc. continue its uptrendDaily Technical Forecast for Quick Gains - Newser
Is it too late to sell Exelixis Inc.Strategy Builder for Growth Focused Traders - Newser
How to use a screener to detect Exelixis Inc. breakoutsRisk Shielded Trade Watch with Analysis - Newser
Investors in Exelixis, Inc. (EXEL) Warned of Potential Securities FraudContact Levi & Korsinsky Today - ACCESS Newswire
Exelixis, Inc. (EXEL) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Signal strength of Exelixis Inc. stock in tech scannersRSI Divergence and Support Breakout Analysis - Newser
Levi & Korsinsky Investigates Possible Securities Fraud by Exelixis, Inc. (EXEL) - ACCESS Newswire
Potential Securities Fraud: Levi & Korsinsky Investigates Exelixis, Inc. (EXEL) - ACCESS Newswire
Exelixis, Inc. (EXEL) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Can Exelixis Inc. recover in the next quarterBuy and Hold Strategy for Capital Safety - Newser
Why Exelixis Inc. stock attracts strong analyst attentionFree Optimized Watchlist With Daily Adjustments - Newser
Avantax Advisory Services Inc. Makes New $551,000 Investment in Exelixis, Inc. (NASDAQ:EXEL) - Defense World
Will Exelixis Inc. see short term momentumFundamental Forecast for Undervalued Stocks - Newser
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Exelixis, Inc. (EXEL) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Securities Investigation: Levi & Korsinsky Investigates Exelixis, Inc. (EXEL) on Behalf of Investors - ACCESS Newswire
Exelixis, Inc. : The cure to cancer? - MarketScreener
Cabometyx Sales Miss Mark in Q2: What Does This Mean for EXEL Stock? - TradingView
Exelixis (NASDAQ:EXEL) Cut to “Buy” at Wall Street Zen - Defense World
Exelixis EXEL Q2 2025 Earnings Call Transcript - AOL.com
Bronstein, Gewirtz & Grossman, LLC Encourages Exelixis, Inc. (EXEL) Investors to Inquire about Securities Investigation - ACCESS Newswire
Live market analysis of Exelixis IncReal Time Growth Signal with Smart Setup - Newser
Don't Overlook Exelixis (EXEL) International Revenue Trends While Assessing the Stock - Yahoo Finance
Exelixis Inc. Chart Enters High Volatility ZoneTriple Digit Return Stock Predictions Released - beatles.ru
Exelixis (EXEL) Tumbles 16.8% as Q2 Earnings Disappoint - MSN
How strong is Exelixis Inc. company’s balance sheetBoost your returns with professional guidance - Jammu Links News
What makes Exelixis Inc. stock price move sharplyMassive wealth growth - Jammu Links News
What are analysts’ price targets for Exelixis Inc. in the next 12 monthsSky-high return potential - Jammu Links News
Is Exelixis Inc. a good long term investmentOutstanding trading profits - Jammu Links News
EXEL ALERT: Levi & Korsinsky Investigates Exelixis, Inc. for Possible Securities Fraud Violations - ACCESS Newswire
How does Exelixis Inc. compare to its industry peersBreakthrough capital growth - Jammu Links News
How many analysts rate Exelixis Inc. as a “Buy”Capitalize on market momentum for maximum profit - Jammu Links News
Did You Suffer Losses in Exelixis, Inc. (EXEL)? Contact Levi & Korsinsky About Securities Fraud Claims - ACCESS Newswire
Why is Exelixis Inc. stock attracting strong analyst attentionBreakthrough profit margins - Jammu Links News
Exelixis Inc Azioni (EXEL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Exelixis Inc Azioni (EXEL) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| WYSZOMIERSKI JACK L | Director |
Jun 03 '25 |
Sale |
43.09 |
7,535 |
324,683 |
358,882 |
3.70%
1.02%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):